SCHEMBL6754154

SCHEMBL6754154

C=C(c1ccc(C(=O)OCC)cc1)c1cc2c(cc1C)C(C)(C)CCC2=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 15/20 0.51
RXRG P48443 9/20 0.51
RXRB P28702 8/20 0.51
RARA P10276 5/20 0.51
RARB P10826 5/20 0.51
RARG P13631 2/20 0.51
MEN1 O00255 1/20 0.51
CYP26A1 O43174 1/20 0.51
ABCB11 O95342 1/20 0.51
ESR1 P03372 1/20 0.51
PGR P06401 1/20 0.51
HTR1A P08908 1/20 0.51
ADRA2A P08913 1/20 0.51
ADORA3 P0DMS8 1/20 0.51
CHRM1 P11229 1/20 0.51
DRD1 P21728 1/20 0.51
TBXA2R P21731 1/20 0.51
SLC6A2 P23975 1/20 0.51
ADRA1A P35348 1/20 0.51
OPRM1 P35372 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6890269 0.85 RXRA (0.70) RXRARXRGRXRBRARARARB
SCHEMBL6752825 0.83 RARA (0.41) RXRARXRGRXRBRARARARB
SCHEMBL6752824 0.83 RARA (0.41) RXRARXRGRXRBRARARARB
SCHEMBL6756015 0.80 RXRA (0.46) RXRARXRGRXRBRARARARB
SCHEMBL8018376 0.80 RARA (0.54) RXRARXRGRXRBRARARARB
Diethylamine SCHEMBL28582419 0.80 RXRA (0.62) RXRARXRGRXRBRARARARB
SCHEMBL6234006 0.80 MAPT (0.50) RARARARBRARGMEN1ESR1
SCHEMBL6234009 0.80 MAPT (0.50) RARARARBRARGMEN1ESR1
Diethylamine SCHEMBL28614252 0.79 RXRA (0.61) RXRARXRGRXRBRARARARB
SCHEMBL8025897 0.78 RXRA (0.43) RXRARXRGRXRBRARARARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713515-B2 ADMINISTERING BENZYL, NAPHTHYL ACID DERIVATIVES BRISTOL MYERS SQUIBB COMPANY 2004-03-30 US disclosed
US-6624154-B1 Invention relates to compositions comprising a retinoid X receptor agonist and an agent capable of activating protein kinase A. The invention also relates to methods of treating hyperproliferative diseases by administering a retinoid X BRISTOL-MYERS SQUIBB COMPANY 2003-09-23 US disclosed
US-20020120006-A1 Retinoic acid receptor antagonists as promoters of angiogenesis BRISTOL-MYERS SQUIBB COMPANY 2002-08-29 US disclosed
WO-2002022113-A2 RETINOIC ACID RECEPTOR ANTAGONISTS AS PROMOTERS OF ANGIOGENESIS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-03-21 WO disclosed
EP-1173061-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES Bristol-Myers Squibb Company (US) 2002-01-23 EP disclosed
WO-2000064260-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES BRISTOL-MYERS SQUIBB COMPANY (US) 2000-11-02 WO disclosed
WO-2000059861-A1 SELECTIVE RETINOIC ACID ANALOGS BRISTOL-MYERS SQUIBB COMPANY (US) 2000-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120006-A1 Retinoic acid receptor antagonists as promoters of angiogenesis RARB, RARG, RARA RXRA 4/4885RXRG 5/4885RXRB 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.